• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Initial Rate of Decline for Response Prediction in Chronic Myeloid Leukemia.慢性髓性白血病反应预测的初始下降率
Turk J Haematol. 2022 Aug 25;39(3):204-205. doi: 10.4274/tjh.galenos.2022.2022.0247. Epub 2022 Jun 14.
2
Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?慢性髓性白血病患者非典型BCR-ABL1融合转录本的定量分析：哪种方法可实现标准化？
Int J Lab Hematol. 2022 Apr;44(2):e67-e68. doi: 10.1111/ijlh.13714. Epub 2021 Sep 29.
3
BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?慢性髓性白血病中的BCR-ABL1突变筛查：下一个会是现在吗？
Lancet Haematol. 2019 May;6(5):e236-e237. doi: 10.1016/S2352-3026(19)30046-8.
4
Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.伴有新型e8a1 BCR-ABL1融合的慢性髓性白血病：尼洛替尼治疗后的快速分子反应
Leuk Lymphoma. 2017 Sep;58(9):1-6. doi: 10.1080/10428194.2017.1281413. Epub 2017 Jan 25.
5
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.酪氨酸激酶抑制剂治疗1个月后早期BCR-ABL1转录本下降作为慢性髓性白血病治疗反应的指标
PLoS One. 2017 Jan 30;12(1):e0171041. doi: 10.1371/journal.pone.0171041. eCollection 2017.
6
Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.慢性髓性白血病中BCR-ABL1激酶结构域突变的反射性筛查
Clin Lab. 2016;62(5):975-6. doi: 10.7754/clin.lab.2015.150938.
7
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.早期 BCR-ABL1 动力学可预测慢性髓性白血病后续无治疗缓解的获得。
Blood. 2021 Mar 4;137(9):1196-1207. doi: 10.1182/blood.2020005514.
8
Evaluation of two CE-IVD tests for transcript monitoring of chronic myeloid leukemia patients.两种用于慢性髓系白血病患者转录本监测的CE-IVD检测方法的评估
Leuk Lymphoma. 2021 May;62(5):1239-1242. doi: 10.1080/10428194.2020.1861274. Epub 2020 Dec 25.
9
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.BCR-ABL1 激酶结构域介导的耐药性对慢性髓性白血病的影响。
Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23.
10
Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.早期BCR-ABL1降低可预测接受任何酪氨酸激酶抑制剂治疗的新诊断慢性髓性白血病患者无事件生存期更佳。
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1.

本文引用的文献

1
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of IS Transcript Levels.慢性髓性白血病分子反应的预测因素：IS 转录本水平的减少率和减半时间。
Turk J Haematol. 2022 Aug 25;39(3):196-203. doi: 10.4274/tjh.galenos.2022.2022-0024. Epub 2022 May 27.
2
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.慢性髓性白血病患者尼罗替尼后续分子反应的早期预测：使用 ABL1 或 GUSB 对照基因定量检测 BCR-ABL1 比值的比较。
J Mol Diagn. 2020 Oct;22(10):1217-1224. doi: 10.1016/j.jmoldx.2020.06.016. Epub 2020 Jul 17.
3
Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value-A Multicenter Study From South India.慢性髓性白血病中 BCR-ABL1 的减半时间：比第 90 天的值更好吗？一项来自印度南部的多中心研究。
Clin Lymphoma Myeloma Leuk. 2020 May;20(5):e205-e211. doi: 10.1016/j.clml.2019.09.606. Epub 2019 Sep 30.
4
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
5
Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.倍增时间和减半时间可能预测慢性粒细胞白血病对酪氨酸激酶抑制剂的反应。
Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019.
6
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.CML 患者接受 BCR/ABL1 激酶抑制剂治疗的血管安全性问题。
Blood. 2015 Feb 5;125(6):901-6. doi: 10.1182/blood-2014-09-594432. Epub 2014 Dec 18.
7
Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.慢性粒细胞白血病（CML）患者的主要分子反应成就可以通过BCR-ABL1/ABL1或BCR-ABL1/GUS比值在比目前推荐更早的随访时间点进行预测。
PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014.
8
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.对于伊马替尼治疗 3 个月后 BCR-ABL1＞10%的 CML 患者，其预后取决于 BCR-ABL1 的下降速度。
Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23.
9
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.早期 BCR-ABL 转录本消除速度作为伊马替尼治疗慢性期慢性髓性白血病（CML）患者的优化预后预测指标。
Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.
10
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.尼洛替尼治疗费城染色体阳性慢性期慢性髓性白血病的伊马替尼耐药或不耐受患者，3 个月时的初始分子反应可预测 24 个月时的反应和无事件生存。
J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29.

Initial Rate of Decline for Response Prediction in Chronic Myeloid Leukemia.

作者信息

Branford Susan

机构信息

Centre for Cancer Biology, SA Pathology, Adelaide, Australia

University of South Australia, School of Pharmacy and Medical Science, Adelaide, Australia

出版信息

Turk J Haematol. 2022 Aug 25;39(3):204-205. doi: 10.4274/tjh.galenos.2022.2022.0247. Epub 2022 Jun 14.

DOI:10.4274/tjh.galenos.2022.2022.0247
PMID:35699277
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9421342/
Abstract
摘要